Morgan Stanley says buy Teva because its turnaround is still in the ‘early innings’

Investing News

Investors should buy shares of Teva Pharmaceutical Industries as the company’s turnaround picks up steam, Morgan Stanley analyst David Risinger said Monday.

Risinger upgraded the stock to overweight from equal weight. He also hiked his price target on the stock to $27 a share, implying a 19.5 percent upside from the stock’s close on Friday. Teva traded around $22.75 on Monday.

“We expect continued improvement in Teva’s financials and investor perception,” Risinger said in a note to clients. “Recall that Teva is just a year into its 3-year restructuring plan, and 25% EBITDA upside in 3Q gave us greater confidence that Teva can deliver additional cost cutting and earnings surprise in coming years.”

Products You May Like

Articles You May Like

3 Cheap Stocks to Buy (Before They Skyrocket)
A new fear takes hold in the market — missing out on the gains
Earnings Are Coming: Buy Shopify Stock While It’s Cheap
Cramer Remix: You’ll want to own this stock when the company gets its groove back
Can Netflix Stock Live Up to the Q4 Hype?

Leave a Reply

Your email address will not be published. Required fields are marked *